Alethea Capital Management
VC Fund
Rancho Santa Fe, United States
Alethea Capital Management is an SEC-registered investment advisor founded in March of 2011. As an investment management and research firm, the mission of Alethea is simple – to provide the highest level of service and guidance to our clients with honesty, integrity, and transparency. The firm’s services include fee-based asset management,research/advanced quantitative systematization, manager/strategy evaluation, and comprehensive planning. Alethea’s center of operations is in San Diego, CA.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Alethea Capital Management invests in
Stages Alethea Capital Management invests in
Countries Alethea Capital Management invests in
Round sizes
Round size
- Series A
- $2.5M–$10M
Investment Focus
Industry
- Health Care 5 (63%)
- Biotechnology 4 (50%)
- Medical 2 (25%)
- Genetics 1 (13%)
- Wellness 1 (13%)
Stage
- Series A 4 (50%)
- Seed 1 (13%)
- Series B 1 (13%)
- Series C 1 (13%)
- Debt Financing 1 (13%)
Country
- United States 5 (63%)
- South Africa 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
PatientPartner
|
PatientPartner personalizes the patient journey by leveraging real-world experiences, educating and guiding patients to make informed medical decisions through connections with doctors, mentors, and physicians. By combining artificial intelligence and machine learning with personalized human connections, the company creates relatable experiencesbetween patients, providers, and industry partners all in one place. Our vision is to create a platform where the world comes to understand their health. A future where all of healthcare can be found on a single platform that is focused on ensuring patients get the care and experiences they deserve. We work with physicians, healthcare institutions and medical technology companies across all healthcare verticals to bring new motivated patients into their clinics, reduce patient drop off, and collect long-term patient outcome data to better identify future patient needs and create better experiences. | $3.5M / Debt Financing / Sep 04, 2024 | |
SEngine Precision Medicine
|
SEngine Precision Medicine uses algorithms and 3D organoid technology to develop drugs with more efficacy. It empowers patients and oncologists with more informed treatment options. The company's technology simultaneously tests more than 200 cancer drugs against a patient's unique tumor organoid outside the body. The results decode themost effective and least toxic treatment options that DNA sequencing alone cannot reveal. Its proprietary platform leverages the aggregated, anonymized test results to develop new cancer-fighting drugs. | $10M / Series A / Jul 28, 2022 | |
|
PatientPartner
|
PatientPartner personalizes the patient journey by leveraging real-world experiences, educating and guiding patients to make informed medical decisions through connections with doctors, mentors, and physicians. By combining artificial intelligence and machine learning with personalized human connections, the company creates relatable experiencesbetween patients, providers, and industry partners all in one place. Our vision is to create a platform where the world comes to understand their health. A future where all of healthcare can be found on a single platform that is focused on ensuring patients get the care and experiences they deserve. We work with physicians, healthcare institutions and medical technology companies across all healthcare verticals to bring new motivated patients into their clinics, reduce patient drop off, and collect long-term patient outcome data to better identify future patient needs and create better experiences. | $2M / Seed / Sep 15, 2020 | |
Lipidio Pharmaceuticals
|
Lipidio Pharmaceuticals is a healthcare company that focuses on advancing a molecule to treat diseases associated with excess body fat. It includes non-alcoholic steatohepatitis, Prader-Willi syndrome, and antipsychotic drug-induced weight gain. The company was founded in 2018 and headquartered in San Diego, California. | Series A / Mar 03, 2020 | |
3X4Genetics
|
Scientifically-robust nutrigenomics (personalised nutrition guided by your own genetic stack). Practitioner education & genomic reporting | $2.5M / Series A / Dec 12, 2019 | |
Presidium Health
|
Presidium Health is a San Diego-based company focused on providing comprehensive healthcare to the medically complex and underserved population utilizing a home-based model of care. The company's offers 24/7 medical triage team, backed by proprietary medical algorithms that guide both acute and chronic disease management, enablingpatients access to comprehensive urgent care services at home which encompasses delivery of medications, labs, and X-rays to the home. | $3.6M / Series A / Nov 19, 2019 | |
Avidity Biosciences
|
Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissueselectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has development efforts focused on immune and other cell types. | $100M / Series C / Nov 13, 2019 | |
|
Avidity Biosciences
|
Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissueselectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has development efforts focused on immune and other cell types. | $16M / Series B / Oct 17, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Alethea Capital Management invest in?
Alethea Capital Management invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Alethea Capital Management's check size?
Alethea Capital Management typically joins rounds of $2.5M–$10M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Alethea Capital Management participates in.
When did Alethea Capital Management last invest?
The most recent investment recorded for Alethea Capital Management closed in Sep 2024. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
